American Headache Society
Dedicated to the study and treatment of headache and face pain.
67th Annual Scientific Meeting
Join us at the premiere event for the latest research and scientific advances underlying the practice of headache medicine.
Education On Demand
Explore headache medicine education and earn CME from the comfort of your home or office.
Shop AHS
15% of proceeds directly supports our research, advocacy, and educational initiatives.
Who We Are
Our goal is to improve the lives of people impacted by migraine and other headache disorders, by encouraging scientific research and educating physicians, health professionals and the public.
Become a Member
AHS is a welcoming community to practicing providers and researchers from diverse training backgrounds. Educational and early career training programs, online CME resources, and networking and mentorship opportunities are just a few of the many benefits available to AHS members.
Member Community
Access to a welcoming member community, numerous opportunities for career development and growth, mentorship, and connections that will last a lifetime.
Headache: The Journal of Head and Face Pain®
Receive articles about the latest in scientific and clinical research with 10 printed issues per year and full online access.
Exclusive Discounts
Save on your first year of Active membership and receive exclusive member rates, access to partner organizations, and more.
Online Resources
Member access to Education On Demand, community portals, exclusive webinars, and more.
Education On Demand
The go-to virtual platform for headache medicine education, resources, and CME from the American Headache Society. Access exclusive content, On Demand recordings, live Q&A sessions, and a hub for all of your CME transcripts and certificates.
Attend an AHS Event
View upcoming events and add important dates to your calendar including the Annual Scientific Meeting, Scottsdale Headache Symposium®, leadership and training programs, and more.
Explore the Latest in Headache Research
Get the latest headache medicine publications in Headache: The Journal of Head and Face Pain®, view research grant opportunities, and peruse our extensive Headache Medicine Research Library.
Leadership Programs
Looking to become a leader in the field of Headache? Consider completing a leadership training program through the American Headache Society to make a difference in the lives of patients living with headache disorders.
Training Programs
Looking to pursue a career in Headache Medicine? Consider completing a headache training program through the American Headache Society to boost your knowledge and kick-start a lifelong journey in the field alongside expert faculty and colleagues.
Stay up to Date on Headache News
Headache on the Hill 2025: Event Recap
New research in Headache evaluates the safety of combining atogepant and ubrogepant for episodic migraine. The TANDEM study offers important insights into dual-therapy tolerability — essential reading for clinicians optimizing treatment strategies.
Advancing Headache Care: 2024 Grant Award Recipients
AHS has announced the 2024 research grant recipients, awarding $1.23M to projects advancing headache care. From AI tools to youth-focused interventions, these initiatives will be presented at future AHS meetings and in peer-reviewed journals.
International Headache Academy 2025: Event Recap
IHA 2025 brought 51 early-career neurologists and researchers together for expert-led sessions, hands-on learning, and mentorship. With a focus on research, clinical practice, and career development, the program continues to shape the future of headache medicine. Applications for IHA 2026 open this summer.
Axsome Therapeutics Announces FDA Approval of AXS-07 (meloxicam and rizatriptan)
Axsome Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved AXS-07 (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. This novel oral medication combines meloxicam, a nonsteroidal anti-inflammatory drug, and rizatriptan, a serotonin receptor agonist, to provide rapid and sustained relief from migraine pain.